$PAXH
PREAXIA HEALTH CARE PAYMENT SYSTEMS INC.

2023 Q2 Form 10-Q Financial Statement

#000126246323000031 Filed on April 19, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $0.00 $0.00 $70.00
YoY Change -100.0% -100.0% -46.15%
Cost Of Revenue $0.00
YoY Change
Gross Profit $0.00
YoY Change
Gross Profit Margin
Selling, General & Admin $36.03K $36.12K $36.37K
YoY Change -4.43% -0.69% -7.69%
% of Gross Profit
Research & Development $1.310K $371.00 $10.50K
YoY Change -88.08% -96.47% 438.46%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $37.34K $36.49K $46.87K
YoY Change -23.31% -22.15% 13.35%
Operating Profit -$37.34K -$36.49K -$46.80K
YoY Change -22.03%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$37.34K -$36.49K -$46.80K
YoY Change -23.26% -22.03% 13.51%
Income Tax
% Of Pretax Income
Net Earnings -$37.34K -$36.49K -$46.80K
YoY Change -23.26% -22.03% 13.51%
Net Earnings / Revenue -66857.14%
Basic Earnings Per Share $0.00
Diluted Earnings Per Share $0.00 $0.00 -$2.367K
COMMON SHARES
Basic Shares Outstanding 19.77M shares 19.77M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $10.00 $30.00 $220.00
YoY Change -96.15% -86.36% 83.33%
Cash & Equivalents $6.00 $32.00 $219.00
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $6.00 $32.00 $220.00
YoY Change -97.68% -85.45% 83.33%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $6.00 $32.00 $220.00
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $6.00 $32.00 $220.00
YoY Change -97.68% -85.45% 83.33%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $398.4K $366.7K $679.1K
YoY Change 42.42% -46.0% 21.41%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $1.699M $1.699M $1.207M
YoY Change 0.29% 40.72% 0.99%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.297M $2.259M $2.092M
YoY Change 7.29% 8.0% 8.95%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $2.297M $2.259M $2.092M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $2.297M $2.259M $2.092M
YoY Change 7.29% 8.0% 8.95%
SHAREHOLDERS EQUITY
Retained Earnings -$5.029M -$4.992M
YoY Change 3.21%
Common Stock $19.77K $19.77K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$2.297M -$2.259M -$2.092M
YoY Change
Total Liabilities & Shareholders Equity $6.00 $32.00 $220.00
YoY Change -97.68% -85.45% 83.33%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$37.34K -$36.49K -$46.80K
YoY Change -23.26% -22.03% 13.51%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$5.660K -$7.950K -$15.99K
YoY Change -70.07% -50.28% 77.27%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change
Cash From Investing Activities $0.00 $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 5.630K 7.800K 16.10K
YoY Change -70.29% -51.55% 76.15%
NET CHANGE
Cash From Operating Activities -5.660K -7.950K -15.99K
Cash From Investing Activities 0.000 0.000 0.000
Cash From Financing Activities 5.630K 7.800K 16.10K
Net Change In Cash -30.00 -150.0 110.0
YoY Change -175.0% -236.36% -8.33%
FREE CASH FLOW
Cash From Operating Activities -$5.660K -$7.950K -$15.99K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
159699 usd
CY2023Q1 paxh Accounts Payable And Accrued Liabilities Related Party
AccountsPayableAndAccruedLiabilitiesRelatedParty
210000 usd
CY2022Q2 paxh Accounts Payable And Accrued Liabilities Related Party
AccountsPayableAndAccruedLiabilitiesRelatedParty
120000 usd
CY2023Q1 paxh Advances Related Party
AdvancesRelatedParty
59316 usd
CY2022Q2 paxh Advances Related Party
AdvancesRelatedParty
32580 usd
CY2023Q1 us-gaap Loans Payable Current
LoansPayableCurrent
173067 usd
dei Entity Central Index Key
EntityCentralIndexKey
0001350156
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--05-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-02-28
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-52365
dei Entity Registrant Name
EntityRegistrantName
PREAXIA HEALTH CARE PAYMENT SYSTEMS INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-4395271
dei Entity Address Address Line1
EntityAddressAddressLine1
PO Box 34075 Westbrook PO
dei Entity Address Address Line2
EntityAddressAddressLine2
1610-37th Street S.W
dei Entity Address City Or Town
EntityAddressCityOrTown
Calgary
dei Entity Address State Or Province
EntityAddressStateOrProvince
AB
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
T3C 3W2
dei City Area Code
CityAreaCode
(403)
dei Local Phone Number
LocalPhoneNumber
850-4120
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
19767698 shares
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
32 usd
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
259 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
32 usd
CY2022Q2 us-gaap Assets Current
AssetsCurrent
259 usd
CY2023Q1 us-gaap Assets
Assets
32 usd
CY2022Q2 us-gaap Assets
Assets
259 usd
CY2023Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
156671 usd
CY2022Q2 us-gaap Loans Payable Current
LoansPayableCurrent
168075 usd
CY2023Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
134792 usd
CY2022Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
134792 usd
CY2023Q1 us-gaap Notes And Loans Payable Current
NotesAndLoansPayableCurrent
466817 usd
CY2022Q2 us-gaap Notes And Loans Payable Current
NotesAndLoansPayableCurrent
466817 usd
CY2023Q1 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
1058760 usd
CY2022Q2 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
1058760 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
2259423 usd
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
2140723 usd
CY2023Q1 us-gaap Liabilities
Liabilities
2259423 usd
CY2022Q2 us-gaap Liabilities
Liabilities
2140723 usd
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0 usd
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0 usd
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19767698 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19767698 shares
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19767698 shares
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19767698 shares
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
19768 usd
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
19768 usd
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2655236 usd
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2655236 usd
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
57197 usd
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
57197 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-4991592 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-4872665 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-2259391 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-2140464 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
32 usd
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
259 usd
CY2023Q1 us-gaap Revenues
Revenues
0 usd
CY2022Q1 us-gaap Revenues
Revenues
70 usd
us-gaap Revenues
Revenues
0 usd
us-gaap Revenues
Revenues
341 usd
CY2023Q1 paxh Consulting Fees
ConsultingFees
30442 usd
CY2022Q1 paxh Consulting Fees
ConsultingFees
30000 usd
paxh Consulting Fees
ConsultingFees
90442 usd
paxh Consulting Fees
ConsultingFees
90785 usd
CY2023Q1 us-gaap Professional Fees
ProfessionalFees
2996 usd
CY2022Q1 us-gaap Professional Fees
ProfessionalFees
3095 usd
us-gaap Professional Fees
ProfessionalFees
12536 usd
us-gaap Professional Fees
ProfessionalFees
14478 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2679 usd
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3272 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10734 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12408 usd
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
371 usd
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10499 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5215 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14653 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
36488 usd
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
46866 usd
us-gaap Operating Expenses
OperatingExpenses
118927 usd
us-gaap Operating Expenses
OperatingExpenses
132324 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-36488 usd
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-46796 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-118927 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-131983 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-36488 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-46796 usd
us-gaap Net Income Loss
NetIncomeLoss
-118927 usd
us-gaap Net Income Loss
NetIncomeLoss
-131983 usd
CY2023Q1 paxh Earning Per Share Basic And Diluted
EarningPerShareBasicAndDiluted
-0.00
CY2022Q1 paxh Earning Per Share Basic And Diluted
EarningPerShareBasicAndDiluted
-0.00
paxh Earning Per Share Basic And Diluted
EarningPerShareBasicAndDiluted
-0.01
paxh Earning Per Share Basic And Diluted
EarningPerShareBasicAndDiluted
-0.01
CY2023Q1 paxh Weighted Average Number Of Shares Outstanding Basic And Diluted
WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
19767698 shares
CY2022Q1 paxh Weighted Average Number Of Shares Outstanding Basic And Diluted
WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
19767698 shares
paxh Weighted Average Number Of Shares Outstanding Basic And Diluted
WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
19767698 shares
paxh Weighted Average Number Of Shares Outstanding Basic And Diluted
WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
19767698 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-2222903 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-36488 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-2259391 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-2140464 usd
us-gaap Net Income Loss
NetIncomeLoss
-118927 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-2259391 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-2045008 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-46796 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-2091804 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-1959821 usd
us-gaap Net Income Loss
NetIncomeLoss
-131983 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-2091804 usd
us-gaap Net Income Loss
NetIncomeLoss
-118927 usd
us-gaap Net Income Loss
NetIncomeLoss
-131983 usd
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
90000 usd
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
90000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-3028 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-3077 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-31955 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-45060 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
us-gaap Proceeds From Loans
ProceedsFromLoans
4992 usd
us-gaap Proceeds From Loans
ProceedsFromLoans
11865 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
27303 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
33584 usd
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
567 usd
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
210 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
31728 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
45239 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-227 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
179 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
259 usd
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
40 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
32 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
219 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Net Income Loss
NetIncomeLoss
-118927 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-31955 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-2259391 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84A_eus-gaap--UseOfEstimates_zgVLRxeMj77b" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i><span style="text-decoration: underline"><span id="xdx_86B_z35TSBva4X4a">Use of Estimates</span> </span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">The preparation of the Company’s unaudited condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in these consolidated financial statements and accompanying notes. Although these estimates are based on management’s knowledge of current events and actions that our company may undertake in the future, actual results could differ from those estimates.</p>
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5215 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14653 usd
CY2023Q1 paxh Revenues From Related Parties
RevenuesFromRelatedParties
0 usd
paxh Revenues From Related Parties
RevenuesFromRelatedParties
70 usd
CY2022Q1 paxh Revenues From Related Parties
RevenuesFromRelatedParties
0 usd
paxh Revenues From Related Parties
RevenuesFromRelatedParties
341 usd
paxh Commissions Earns Percentage
CommissionsEarnsPercentage
0.10 pure
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
567 usd
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
210 usd
CY2023Q1 us-gaap Loans Payable Current
LoansPayableCurrent
173067 usd
CY2022Q2 us-gaap Loans Payable Current
LoansPayableCurrent
168075 usd
us-gaap Proceeds From Loans
ProceedsFromLoans
4992 usd
us-gaap Proceeds From Loans
ProceedsFromLoans
11865 usd
paxh Repayment Of Loans Payable Shareholder
RepaymentOfLoansPayableShareholder
0 usd
paxh Repayment Of Loans Payable Shareholder
RepaymentOfLoansPayableShareholder
0 usd
CY2023Q1 us-gaap Notes And Loans Payable Current
NotesAndLoansPayableCurrent
466817 usd
CY2023Q1 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
1058760 usd
CY2022Q2 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
1058760 usd
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19767698 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19767698 shares
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19767698 shares
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19767698 shares

Files In Submission

Name View Source Status
0001262463-23-000031-index-headers.html Edgar Link pending
0001262463-23-000031-index.html Edgar Link pending
0001262463-23-000031.txt Edgar Link pending
0001262463-23-000031-xbrl.zip Edgar Link pending
ex31.htm Edgar Link pending
ex32.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
paxh-20230228.xsd Edgar Link pending
paxh22823q.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
paxh-20230228_cal.xml Edgar Link unprocessable
paxh-20230228_lab.xml Edgar Link unprocessable
paxh-20230228_def.xml Edgar Link unprocessable
paxh-20230228_pre.xml Edgar Link unprocessable
paxh22823q_htm.xml Edgar Link completed
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending